SOD1 and amyotrophic lateral sclerosis: They determined that more than half of the hits targeted the Src/c-Abl signaling pathway, and they identified that bosutinib (Figure 1) increased ALS motor neuron survival (mean survival: 164.1 ± 9.4 days compared to vehicle (156.3 ± 8.5 days)) and regulated misfolded SOD1 proteins in transgenic mice.